These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Request To Download Free Sample of This Strategic Report @ Highlighted with 41 tables and 85 figures, this 159-page report ?Asia Pacific Biopharmaceuticals Market 2023-2033 by Product Type, Testing ...

Biocon plans to list its biosimilars business by March 2026 and aims for a double-digit market share in the U.S. for five new biosimilars launching next fiscal year. The U.S. market, already ...

LifeArc Ventures, which invests in innovative early-stage life science companies as part of LifeArc, today announced substantial progress ...

Biosimulation Market size is expected to be worth around US$ 10.1 Billion by 2032 from US$ 303 Billion in 2023, growing at a CAGR of 13.7% ...

The early morning operation targets multiple properties in Dover, Deal, Thanet and Aylesham. A report says the existing facility in Hartlepool's Whitby Street is in a deteriorating condition.

A West Virginia University legal scholar says current laws may be giving manufacturers of biologic drugs, like antibodies and flu vaccines, too much in the way of legal protections before copycat ...

and other therapies that are approved by the FDA’s Center for Biologics Evaluation and Research. Among 2024’s notable new drugs were three approvals for antibiotic therapies: Allecra ...

OKYO Pharma Ltd (the "Company"), a biotechnology firm specializing in biological products with a current market capitalization of $36.54 million, announced today that it has obtained $1.4 million in ...

Company Anticipates Submitting for U.S. Accelerated Approval in H1 2026 - WALTHAM, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage neuromuscular ...

Ruth Goldberg Jaskow, who's 101 years old, has an unusual fitness goal: She wants to live to 103 to "beat" her husband. Goldberg Jaskow, who lives in New York and worked as a teacher, has always ...

One of the criteria laid out in the IRA legislation was that drugs must have been approved by the FDA at least seven years earlier (or 11 years for biologics). CMS will conduct negotiations with ...